Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Stada Generics Takes A Hit Even As Firm Steals A March On Rivals
Group’s Sales ‘Better Than The Average For The Top-Five Suppliers’
Sep 02 2021
•
By
Dean Rudge
Stada Generics adjusted EBITDA fell by 12% • Source: Alamy
More from Biosimilars
More from Products